Fiscal 2019 Second Quarter Highlights Net sales of $91.5 million , an increase of 5.5% year over year Gross margin expanded 440 basis points year over year to 53.7% GAAP EPS of $0.06 per share; adjusted EPS of $0.22 per share Cash provided by operations of $13.0 million ; capital expenditures of

LATHAM, N.Y. --(BUSINESS WIRE)--Dec. 20, 2018-- AngioDynamics, Inc.  (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer , President and Chief Executive Officer, and

LATHAM, N.Y. --(BUSINESS WIRE)--Dec. 10, 2018-- AngioDynamics, Inc.  (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the second quarter of

Fiscal 2019 First Quarter Highlights Net sales of $85.3 million , flat versus prior year Gross margin expanded 380 basis points year over year to 52.1% GAAP EPS of $(0.01) per share; adjusted EPS of $0.16 per share Cash used in operations of $8.9 million ; capital expenditures of $0.7 million

LATHAM, N.Y. --(BUSINESS WIRE)--Sep. 19, 2018-- AngioDynamics, Inc.  (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Michael C. Greiner , Executive Vice President and Chief

LATHAM, N.Y. --(BUSINESS WIRE)--Sep. 13, 2018-- AngioDynamics, Inc.  (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the first quarter of

LATHAM, N.Y. --(BUSINESS WIRE)--Sep. 13, 2018-- AngioDynamics, Inc. (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease and oncology, today announced an agreement to acquire RadiaDyne, a privately held medical

LATHAM, N.Y. --(BUSINESS WIRE)--Aug. 23, 2018-- AngioDynamics , Inc. (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease and oncology, today announced that it will present at the following two investor conferences in

LATHAM, N.Y. --(BUSINESS WIRE)--Aug. 15, 2018-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease and oncology, today provided a corporate update on enhancements made to its Oncology business and

Fiscal 2018 Fourth Quarter Highlights Net sales of $88.3 million , an increase of 1.6% year over year Gross margin expanded 500 basis points year over year to 53.7% GAAP EPS of $0.06 per share; adjusted EPS of $0.20 per share Operating cash flow of $23.8 million ; free cash flow of $23.0 million

LATHAM, N.Y. --(BUSINESS WIRE)--Jun. 21, 2018-- AngioDynamics , Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, surgery and oncology, today announced that it will report financial results for the fourth

LATHAM, N.Y. --(BUSINESS WIRE)-- AngioDynamics , Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, surgery and oncology, today announced that it will present at the following two investor conferences in May:

Fiscal 2018 Third Quarter Highlights Net sales of $83.9 million , a decrease of 2.0% year over year Gross margin expanded 300 basis points year over year to 54.2% GAAP EPS of $0.37 ; Adjusted EPS of $0.25 per share Announced the launch of a wireless ultrasound device FDA granted Breakthrough

LATHAM, N.Y. --(BUSINESS WIRE)-- AngioDynamics , Inc. (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, surgery and oncology, today announced that Michael C. Greiner, Executive Vice President and Chief Financial

LATHAM, N.Y. --(BUSINESS WIRE)-- AngioDynamics , Inc. (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, surgery and oncology, today announced that it will report financial results for the third quarter of fiscal

LATHAM, N.Y. --(BUSINESS WIRE)-- AngioDynamics , Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, surgery and oncology, today announced that Jim Clemmer , President and Chief Executive Officer, and Michael C.

LATHAM, N.Y. --(BUSINESS WIRE)-- AngioDynamics , Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, surgery and oncology, today announced that the United States Food and Drug Administration (FDA) has granted

Fiscal 2018 Second Quarter Highlights Net sales of $86.7 million , a decrease of 2.6% year over year U.S. GAAP EPS of $0.01 ; Adjusted EPS of $0.16 per share Operating cash flow of $10.2 million ; free cash flow of $9.4 million LATHAM, N.Y. --(BUSINESS WIRE)-- AngioDynamics , Inc. (NASDAQ:ANGO), a

LATHAM, N.Y. --(BUSINESS WIRE)--Dec. 19, 2017-- AngioDynamics , Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced that Jim Clemmer , President and Chief Executive Officer,

LATHAM, N.Y. --(BUSINESS WIRE)--Dec. 11, 2017-- AngioDynamics , Inc. (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced that it will report financial results for the second